New pill aims to slow lung scarring in IPF patients
NCT ID NCT06764862
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This phase 2 trial tested an experimental tablet called HSK44459 in 186 adults with idiopathic pulmonary fibrosis (IPF), a progressive lung-scarring disease. Participants took one of three doses of the drug or a placebo twice daily for 12 weeks. The main goal was to see if the drug could improve or preserve lung function, measured by forced vital capacity (FVC).
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
HSK44459
What this could lead to
If successful, this could point toward a new oral treatment to slow lung function decline in people with idiopathic pulmonary fibrosis.
What could go wrong
This is a mid-stage trial with only 186 participants over 12 weeks, so results may not confirm long-term benefit or safety. The drug may not improve lung function more than placebo.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for IDIOPATHIC PULMONARY FIBROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Peking Union Medical College Hospital
Beijing, Beijing Municipality, 100000, China